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PENGEKSYRAKAN REITROPOIETIN REKONBINAN MENGGUNA KOLUM 
IMUNOAFINITI DAN PENGESANAN ISOFORM MELALUI 
ELEKTROFORESIS KAPILARI 
 
 
ABSTRAK 
 
                Eritropoietin (EPO) adalah suatu hormone glikoprotein endogenous.  Ia 
disintesiskan di dalam buah pinggang dan dirembes oleh organ yang sama.   Dalam 
pasaran, terdapat sebilangan bahan farmaseutikal termasuk EPO rekombinan (rEPO) 
yang mempunyai kegunaan klinikal.  Dengan perkembangan teknologi novel dalam 
bidang farmaseutikal dan perubatan, “EPO biosimilar”  telah diperkenalkan ke dalam 
pasaran.   Sungguhpun EPO rekombinan telah luas digunakan untuk merawat pelbagai 
jenis anemia, ia juga telah menjadi drug yang terkenal oleh kerana penyelahgunaannya 
dalam sukan berprestasi tinggi.  Pihak berkuasa sukan telah melarang penggunaan rEPO 
semenjak 1989.   Penyelidikan ini telah mengguna beberapa teknik untuk penulenan 
EPO semulajadi serta juga bentuk EPO rekombinan dari air kencing.  Dua teknik kolum 
imunoafiniti (IAC) telah digunakan untuk penulenan EPO; ini adalah  “HiTrap Affinity 
Column” dan “MAIIA EPO Purification Kit”.  Kedua kolum berjaya digunakan untuk 
menahan molekul EPO.  Pemulihan semula EPO dari “HiTrap column” didapati tidak 
berkesan manakala pemulihan semula menggunakan “MAIIA affinity column” agak 
memuaskan. 
 
                 Penyelidikan ini juga menghuraikan suatu kaedah pencirian yang novel 
mengguna Elektroforesis Kapilari (CE) yang dapat digunakan dalam Kawalan Kualiti 
  
  xix 
farmaseutikal dan telah diselidik dari segi keupayaannya untk mengesan 
penyelahgunaan drug dalam sukan.  Kaedah CE konvensional biasanya mengguna suatu 
label yang terikat pada EPO untuk tujuan pengesanan.   Pendekatan ini sungguhpun 
sensitif, berupaya melibatkan bias ke dalam analisis dan ini boleh menjejas 
perbandingan analisis diantara rEPO dan EPO semulajadi.  Penyelidikan ini berasaskan 
pendekatan, yang ringkasnya mengguna cahaya UV dan algoritma tanpa bias bagi 
mengurangkan masalah seperti ini.  Oleh kerana kedua EPO semulajadi dan rekombinan 
terdapat secara fisiologikal di dalam air kencing pengguna, suatu pendekatan yang dapat 
membezakan diantara hormon semulajadi dan EPO rekombinan eksogenous amat 
diperlukan.  Analisis ini mungkin dapat digunakan untuk kawalan antidoping.   Baru-
baru ini, pengasingan rEPO kepada populasi glikoform berasingan telah menjadi suatu 
cabaran besar terutamanya apabila kepekatan hormone yang agak rendah bagi ujian 
anti-doping.   Tujuan penyelidikan ini adalah untuk membangunkan pengesanan 
glikoform EPO yang berkesan, sensitif dan pantas di dalam matriks air kencing.  
Pembangunan elektroforesis kapilari (CE) telah memainkan peranan penting dalam 
memperkenalkan aplikasi terkini dalam pengesanan glikoform rEPO.  Walau bagaimana 
pun, sensitiviti kaedah ini mempunyai paras pengesanan LOD pada 3000 IU, dan ini 
menghadkan penggunaannya dalam analisis antidoping oleh kerana paras EPO yang 
begitu rendah dalam air kencing.  Penyelidikan ini telah menunjukkan keupayaan CE 
dalam pengasingan kandungan glikoform yang kompleks dalam EPO dan ini 
mewujudkan buat kali pertamanya pendekatan CE tanpa penggunaan label bagi 
Pengawalan Kualiti (QA).  
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RECOMBINANT ERYTHROPOIETIN EXTRACTION BY 
IMMUNOAFFINITY COLUMN AND THE DETECTION OF ISOFORMS 
USING CAPILLARY ELECTROPHORESIS 
 
 
ABSTRACT 
 
                Erythropoietin (EPO) is an endogenous glycoprotein hormone.  It is 
synthesized in and secreted mostly by the kidneys.  In the market, there are a number of 
pharmaceuticals of recombinant EPO (rEPO) for clinical use.  With the advent of novel 
technologies in the pharmaceutical and therapeutic areas, recombinant EPO have been 
introduced into the market.  Although recombinant EPO has been broadly used to treat 
various forms of anaemia, it has also become a very well known drug due to its misuse 
in endurance sports.  Sport authorities have prohibited the use of rEPO since 1989.  This 
work has used a number of techniques to purify natural EPO and the recombinant form 
from the urine.  Two Immunoaffinity column techniques (IAC) were used to purify 
EPO i.e. HiTrap Affinity Columns and MAIIA EPO Purification Kit.  Both columns 
were successfully able to trap EPO molecules.  EPO recovery from the HiTrap columns 
was negligible < 1%, whereas the recovery of MAIIA affinity column was satisfactory.      
 
                 The work has also developed a novel characterization tool using Capillary 
Electrophoresis (CE) that can be used in pharmaceutical Quality Control (QC) and has 
been investigated for its ability to detect drug misuse in sport.  Conventional CE tools 
generally use a label that attaches to the EPO for identification.  These approaches 
though sensitive, can introduce biases into an analysis that could prove inimical to a 
  
  xxi 
comparison between rEPO and EPO samples.  We have used a tool that simply uses UV 
absorption and unbiased algorithms to minimize any such problem.  Since both natural 
and recombinant EPOs are physiologically present in urine, there is an absolute need for 
an approach, which can differentiate between the natural hormone and the recombinant 
exogenous EPO.  The analysis may have some utility for anti-doping control. The 
separation of intact rEPO into distinct glycoform populations has recently been a great 
challenge to achieve particularly in low concentrations for anti-doping world.  The aim 
of this work is to develop a sensitive, rapid and cost effective detection of rEPO 
glycoforms in urine matrix.  The development of capillary electrophoresis (CE) has 
played a key role in bringing about the modern applications of rEPO glycoforms 
detection.  However, the sensitivity of this method used has an LOD level of 3000 IU, 
which limits its use in sport world due to the low level of EPO in urine that is much 
lower than the real value.  We show in this study the ability of CE in separating 
complex glycoform content of rEPO allowing for the first time unbiased approach to 
Quality Assurance (QA) using label-free approach. 
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CHAPTER 1 
 
1.1 Introduction 
 
                Competition is a natural instinct in the human nature, which has been 
essential from both evolutionary and survival point of view (Giuseppe, et al, 2006).  In 
sport the use of illegal drugs to deceitfully increase aerobic performance, has plagued 
the world of competition for ages (Grégory, et al, 2006. Osquel, et al, 2008).  Doping is 
now a global problem that follows international sporting events worldwide (David, et al, 
2007).  Although athletic performance enhancement has been achieved since ancient 
competitions by using various diets, training routines and hard work, it can be also 
achieved by using a wide variety of physiological, mechanical and pharmacological 
doping techniques (David A et al, 2007).    
 
                In sports, doping refers to the use of performance-enhancing drugs, 
particularly those forbidden by organizations that regulate competitions.  This definition 
is established by the medical commission of the International Olympic Committee 
(IOC) that is based on the prohibition of certain types of pharmaceuticals.  It took 
several decades for sport organizations to realize the magnitude of the threat that doping 
poses to fair play, and the hazards it presents to the health and well-being of athletes.   
This phenomenon thereby triggered the recent establishment of the systemic fight 
against doping (Osquel, et al, 2008). 
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               In 1967 the International Olympic Committee established the medical 
commission that launched the introduction of anti-doping regulations, including the first 
official list of prohibited substances (Osquel, et al, 2008).  The committee has attempted 
to stop the spread of doping problems for the past half century with minor effects 
(David, et al, 2007).  In 1999 the World Anti-Doping Agency (WADA) was created as a 
result of the IOC-convened World Conference on Doping in Sport, where both the IOC 
and government agreed to create an independent agency to sponsor, coordinate, and 
monitor the fight against doping in sports internationally.  Some of the main WADA’s 
responsibilities are the creation and implementation of the World Anti-Doping Code 
and the related International Standards.  The code represents the foundation stone for 
bringing all sport anti-doping regulations of all countries together.  The World Anti-
Doping Code, therefore, defines doping as the incidence of an anti-doping rule abuse 
(Osquel, et al, 2008).   
 
                According to the code, there are three criterions in which two have to be met 
for a substance to be added to the Prohibited List.  First, it’s potentiality to enhance 
sport performance.  Second, its health risk for the athlete.  Third, sport’s spirit 
opposition. 
  
                The performance-enhancing effects of any particular substance are: 1- 
Ergogenic effect that includes enhanced strength, higher energy production and better 
recovery.  2- Anabolic potential that includes increased protein synthesis particularly in 
the muscles.  3- Motivating properties by increasing attention and loss of fear.  These 
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substances grant a competitive advantage to athletes.  The Code establishes the 
principle of “strict liability”, in which the presence of any prohibited substance or its 
metabolite in an athlete’s specimen is adequate to represent an anti-doping rule 
desecration, irrespective of the athlete’s personal intention for using such illegal 
enhancers (Osquel, et al, 2008).      
 
               There are two different origins for prohibited substances: 1- Exogenous, which 
are substances that cannot be naturally produced by the body.  For example, synthetic 
Anabolic Androgenic Steroids (AAS), including methyltestosterone and nandrolone.  2- 
Endogenous, those are substances produced naturally by the body, such as, human 
growth hormone (hGH), erythropoietin (EPO), testosterone, dehydroepiandrosterone, 
and insulin (Osquel, et al, 2008).    
  
                In Olympic and professional sports, performance enhancement drugs have 
become a medical, ethical and legal problem for current athletes and athletic 
organizations.  Although it was thought that with educational programs, testing and 
supportive medical treatment, drug-abusing behavior would diminish, this has not been 
the case.  This is predominantly due to the amount of money coupled with winning the 
competition in today’s sports industry.  Because athletes are being rewarded for 
winning at nearly every level of competition, coaches would sacrifice and risk a great 
deal in order to obtain a competitive rim and enhance performance at all coasts (Osquel, 
et al, 2008).  
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1.2 Objectives    
1- To establish a sensitive, selective and cost effective method for sample clean-up 
for EPO extraction. 
 
2- To investigate the utility of capillary electrophoresis to isolate recombinant EPO 
isoforms using label-free approach on CZE, striving to provide an alternative 
technique to the current WADA-accredited approach. 
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CHAPTER 2 
LITERATURE REVIEW 
 
2.1 Hormone Abuse in Sports  
 
                Hormone abuse by athletes may lead to serious health problems for 
individuals, as well as the destruction of the competition’s spirit among athletes, 
officials and spectators in sport (M Verroken, 2001).   Therefore, the abuse of hormonal 
substances in sport is prohibited.  The higher authorities in sport attempt to establish 
rules and regulations in order to stop hormone abuse among athletes.  They are also 
working on those athletes who have worked around these rules, challenging themselves 
to the extent that the anti-doping system itself is questioned.  Testing for hormone abuse 
is very challenging as these hormones are also endogenously produced, for that reason, 
hormone analytical results requires careful review.  Since some findings might be 
indications of some medical conditions, results interpretation needs a hypersensitive 
handling to obtain accurate results (M Verroken, 2001).   
 
                 Athletes at the ancient Olympic Games had special diets to advance their 
physical capabilities.  At the 668 BC Olympic Games, the winner of the 200 m sprint 
was said to use special diet of dried figs.  This picture is not so far from the supplements 
that are consumed by the athletes in today’s athlete’s sports nutrition support programs 
(Finlay & Plecket 1976).   
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                Examining the popularity of hormone abuse by theoretical perception on 
ethics, allows a philosophical study of the dilemmas facing sports as well as a better 
identification of issues that can help in resolving the problem of doping.  Approaching 
the popularity of hormone abuse from ethical prospective puts the first step to examine 
what is acceptable, permitted and where the dividing lines are supposed to be drawn.  
For instance, in general sports medicine and medicine are governed by an ethic that is 
dedicated to restore and repair the form and function of human being as humanly as 
possible (M Verroken, 2001).  The data collected from the testing programs provide one 
guide to the actual popularity of hormone abuse.  However, since not all findings are 
considered doping offences, this cannot be used as a definite guide to the extent of 
hormone abuse.  Also, as mentioned above, the use of hormone treatment with or 
without therapeutical indication promotes more complications to the disciplinary 
process.  Accordingly, the door is open for the anti-doping system to be subjugated by 
dishonest scientists, raising challenges that examine the limit of credibility.  Thus, a 
close collaboration between scientists and sport is needed to prevent the athletes from 
becoming victims of the rules proposed to protect sport (M Verroken, 2001). 
 
2.2 Hormones as Doping Agents – Overview  
 
2.2.1 Anabolic Androgenic Steroids 
 
                Anabolic androgenic steroids are examples of doping agent.  They are related 
to the male hormone testosterone (Handelsman,  2006).  Due to its augmenting effect on 
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muscle mass and strength, AAS are amongst the most frequently detected drugs in sport 
(Osquel, et al, 2008).  Despite the serious adverse effects associated with the use of 
these drugs, AAS misuse by athletes and non-athletes are the same, including 
schoolchildren.  The adverse effects include, reduced fertility and gynecomastia in 
males, masculinization in women, as well as cardiovascular complications, cancer, liver 
toxicity and behavioral disorders (Sánchez, et al, 2008).  Moreover, the irreversible 
damage to organs occurs following chronic high-dose usage. There is also a tendency 
for taking harmful high doses of AAS in combination with other performance-
enhancing drugs, such as human growth hormone (hGH) (Parkinson, et al, 2006). 
 
                    What makes AAS an easy choice for athletes, risking their health to get an 
undeserved competitive advantage, are: 1- The strong and long-lasting benefits to 
performance obtained by these agents, 2- The documented attempts to develop new 
generation of sophisticated up-market AAS that are more and more difficult to detect 
(Osquel, et al, 2008). 
  
                 There are a number of approaches that have been developed in order to detect 
these compounds including designer steroids, such as Tetra-Hydro-Gestrinone (THG) 
and Desoxy-Methyl Testosterone (DMT).  The analytical methods that have been 
employed are based on the combination of chromatographic Liquid Chromatography or 
Gas Chromatography and Mass Spectrometric, as well as Isotope Ratio MS (IRMS).   
The WADA accredited laboratories worldwide successfully implement these methods 
(Osquel, et al, 2008). 
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                The increased awareness of the anti-doping authorities that is led by WADA, 
in addition to the back up and growing support from the law-enforcement agencies and 
the pharmaceutical industry.  All the forementioned in combination with the 
development of more sophisticated detection methods, has resulted in the successful 
identification and banning of newly developed performance-enhancing drugs, including 
designer steroids.  Yet, the outcomes of these investigations have shown continued 
widespread use of prohibited substances by athletes, despite their awareness of the risk, 
which can be the termination of their sporting career as a result of anti-doping violation 
(Osquel, et al, 2008). 
 
2.2.2 Peptide Hormones 
 
                In recent times, the misuse of endogenous hormones have noticeably 
increased as a result of a number of factors including, the development of molecular 
biology techniques particularly the recombinant DNA technology.  This technology has 
pumped the market with quite cheap synthetic hormones.  Accordingly, the 
development of this technique has contributed in the elimination of some of the risks 
associated with the use of purified hormones, for instance, the elimination of 
Greutzfeldt-Jacob disease following the administration of hGH isolated from cadaveric 
pituitary glands (Buchanan, et al, 1991). 
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                The prohibited substances and their releasing factors are: 1-Erythropoietin 
(EPO), 2-Insulin-like Growth Factors (IGF, e.g. IGF-I and Mechono Growth Factors 
(MGF), 3-Gonadotrophins (e.g. Luteinising Hormonr (LH) and Human Chorionic 
Gonadotropins (HCG), 4-Insulin and 5-Corticotrophins.  Endogenous peptide hormones 
with capability of performance enhancing properties are listed in WADA’s prohibited 
substances list under S2 section “Hormones and related substances”. All other 
substances with comparable chemical composition or comparable biological outcomes 
are found under this section as well (Osquel, et al, 2008). 
 
                The time window for the detection of peptide hormones is extremely short, 
due to their rapid degradation and clearance from the body.   Additionally, the 
significant similarity between the endogenous (naturally produced) and exogenous 
(manufactured) peptide hormones, in their structure and biochemical properties, makes 
their detection extremely demanding and challenging.  To date, the detection of these 
large and complex proteins is based on immunological identification of each substance 
by specific antibodies.  Although, there have been attempts to detect these hormones by 
Mass Spectrometry based techniques (M Verroken, 2001, Handelsman DJ. 2006, Liu C 
et al. 1996). 
   
2.2.3 Gonadotropins 
 
                Human chorionic gonadotropin (hCG) is a glycoprotein that belongs to a 
family of peptide hormones that also includes thyroid stimulating hormone (TSH), 
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follicle-stimulating hormone (FSH) and luteinizing hormone (LH) (Stenman, et al. 
2004, Pierce, et al. 1981).   It is produced in abundance by the placental trophoblastic 
cells during pregnancy that also stimulates the production of steroid hormone in the 
ovaries (Stenman, et al. 2004).  The hormone is highly glycosylated with β-carboxy 
terminus.  The β-carboxy terminus facilitates its detection by certain antibodies or via 
mass spectrometry (Gam LH, et al. 2003, Birken, et al. 2003, Birken, et al. 1982).  
 
                Human cherionic gonadotropin has been used for doping due to its 
stimulating effect on the production of endogenous steroid hormone that increase 
testosterone levels without affecting the testosterone/epitestosterone ratio.  The 
testosterone/epitestosterone ratio is used as a criterion for detecting doping with 
exogenous testosterone. The use of hCG cannot be ignored, despite hCG not being 
widely abused (de Boer D et al. 1991, Johnson, et al, 1993). 
 
                Luteinizing Hormone is synthesized and secreted via gonadotropes of the 
anterior lobe of the pituitary gland.  The hormone mediates its biological activity all 
through the same receptor as hCG (Stenman, et al. 2004).  On one hand the hormone 
mid-cycle rush triggers ovulation and encourage the synthesis of progesterone and 
estrogen in females.  On the other hand, it stimulates the production of testosterone by 
leydig cells in men (Robinson, et al. 2007, Wunsch, et al. 2007).  Human menopausal 
gonadotrophin is a collection of FSH and LH that has the capability to be misused for 
performance-enhancing intentions.   
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                At present, the existence of hCG and LH is considered a doping violation 
when detected above certain values in male athletes.  However, in female athletes, 
establishing the origin of these peptide hormones whether they are exogenous or 
naturally produced is considered a challenging task (Osquel, et al, 2008).  Human 
chorionic gonadotropin in particular may stay high for a number of weeks following 
premature spontaneous miscarriage.  Therefore urinary hCG detection in female athlete 
may reveal unrecognized pregnancy, accordingly risking an invasion of privacy.  
Moreover, in disparity to men, hCG is reported to have insignificant effects on blood 
testosterone levels in women (Handelsam, 2006).  
 
                Urine doping analysis of hCG and LH is done by immunoassays using panels 
of hormone specific antibodies.  Nevertheless, some of these contemporary techniques 
have inherent limitations.  Therefore, new and more specific methods based on tandem 
mass spectrometry (MS/MS) and high performance liquid chromatography (HPLC) 
combined with MS/MS has been developed all through WADA-sponsored research 
(Bowers, 1997, Leinonen, 1999). 
 
2.2.4 Human Growth Hormone 
 
                Human growth hormone (hGH) is a single chain polypeptide hormone 
synthesized and secreted predominantly in the somatotroph cells of the pituitary gland.  
The hormone is species specific that stimulates many metabolic processes in cells.  It 
affects protein, fat, carbohydrates and mineral metabolism (Chawla, et al, 1983, 
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Daughaday, et al, 1965, Ehrnborg, et al, 2000).  Currently, hGH is considered one of the 
most widely abused performance-enhancing agent (Osquel, et al, 2008). 
                 
                Human growth hormone is a 22-kDa molecule that exists as a complex 
combination of several isoforms.  The isoforms resulted from alternative mRNA 
splicing (20 kDa and 17.5 kDa) or as a result of proteolytic cleavage of the mature 
protein (DeNoto, et al, 1981, Lecomte, et al, 1987, Lewis, et al, 1978). 
 
                Recombinant hGH (rhGH) structurally and biochemically impossible to 
differentiate from the 22 kDa endogenous isoform. It has been found that when given to 
GH-deficient individuals, it increased exercise time and maximal oxygen consumption 
(VO2 max) after 6 months of treatment (Beshyah, et al, 1995, Cuneo, et al, 1991).  Also 
it increases body muscle mass, decreases body fat, increases cardiac output and 
improves wound healing (Ehrnborg, et al, 2000, Salomon, et al, 1989).  
 
                Detection of doping with hGH constitutes a great challenge for anti-doping 
laboratories.  A novel approach to detect doping with rhGH, described as the isoform 
differential immunoassay, has been proposed by Prof. Christian Stransburger and Drs 
Zida Wu and Martin Bidlingmmaier (Bidlingmmaier, et al, 2000, Wu Z et al, 1999).  
The assay is developed to detect hGH doping by utilizing the differences in the 
magnitude of hGH isoforms under physiological conditions and following doping 
practice.  It is based on the concept that the composition of hGH in blood is a 
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combination of different isoforms present at constant relative proportions.  Whereas, the 
rhGH is comprised only from the 22-kDa molecular form (Osquel, et al, 2008).     
                               
                Exogenous rhGH increases the concentration of the 22-kDa isoform.  It also 
suppresses the non 22-kDa concentrations for up to 4 days.  Accordingly, the natural 
ratios established between these hGH isoforms (Wallace, et al, 2001).  Recognizing the 
monomeric 22-kDa hGH or a mixture of pituitary derived hGH isoforms through two 
different immunoassays that employ antibodies, the elevated ratios of 22-kDa hGH to 
pituitary derived hGH isoforms are used to designate doping with rhGH (Osquel, et al, 
2008).                                 
 
2.3 Erythropoietin 
 
                Erythropoietin (EPO) is an endogenous glycoprotein hormone (Jordi, et al, 
2007).  It was discovered in the 19th century upon observations of pallor renal diseased 
patients (Joanne, 2006).  The observations are based on the hypothesis made by Cornot 
and De Flandre in 1906.  They suggested that there is a hormonal factor involved in the 
regulation of haemopoiesis (formation of blood cells) (Jordi, et al, 2007).  They used the 
term ‘haemopoietin’ to describe the hormonal substance in their study on animals.  This 
work cemented an upcoming breakthrough made by Bondsdorff and Jalvisto 40 years 
later, who were able to link solely EPO with red blood cell production (Bondsdorff, et 
al, 1948).  In the 1950s scientific and clinical findings established by Jacobson and his 
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co-workers were the determined factors behind the evidence, that the kidneys are the 
main sites of EPO production (Jacobson, et al, 1957). 
 
                In adult humans, EPO is synthesized in and secreted mostly by the kidneys 
(Jordi, et al, 2007).  The peritubular fibroblasts of the kidney’s renal cortex cells is the 
primary site for its synthesis, which accounts for approximately 90% of all systemic 
EPO (Chikuma, et al, 2000).  The liver produces up to 10% of the total hormone formed 
in the body (Emmanuelle, et al, 2003).   Also there is evidence that the brain and uterus 
contribute minor amounts of EPO (Chikuma, et al, 2000, Maria, et al; 2008).  The 
hormone induces red blood cells proliferation, which increases their mass number and 
hence improves oxygen transport and delivery to the tissues.  This improvement in 
oxygen delivery is achieved by increasing haemoglobin concentration within the cell, 
which maximizes oxygen uptake (Figure 2.1) (Emmanuelle, et al, 2003, Jordi, et al, 
2007, Rafael, et al, 2003). 
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Figure 2.1: Erythrocyte production (Erythropoiesis). Adapted from 
http://www.hdcn.com/symp/05anna/02/pet1/pet1.htm 
 
Moreover, EPO plays a major role in the maturation of erythroid precursor cells in the 
bone marrow (Osquel, et al, 2008, Venke, et al, 2001).  From there, EPO is considered 
the main regulator of erythropoiesis (regulation of red blood cell production) (Erslev, 
1991, Jordi, et al, 2007, Rafael, et al, 2003).  It has a crucial physiological feedback 
mechanism in maintaining red blood cells number in the blood stream and in 
maintaining sufficient levels of oxygen supply to the tissues (Estela, et al, 2009).   
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2.3.1 Erythropoietin Structure 
 
2.3.1.1 Human Erythropoietin (Endogenous) 
 
                Human EPO (hEPO) is a 30-kDa glycoprotein with a hormonal activity of 
70,000 IU/mg (Maria, et al, 2008, Rafael, et al, 2003).  The mature protein consists of 
166-amino acid polypeptide chain with a molecular weight of of 18,398 Da for the 
protein moiety (Jorge, et al, 2005, Por-Hsiung, et al, 1985, Venke, el at, 2001).  
Nevertheless, due to the post-translation modifications, the C-terminal arginine is 
removed (M.A. Recny et al, 1987).  The polypeptide chain contains 3 more basic amino 
acids than acidic ones.  The molecule holds irregular distributed charged residues that 
have estimated to be 27% of the total protein.  These residues are not found in region 
77-88, whereas the NH2- and C-terminal ends are highly charged (Por-Hsiung, et al, 
1985).   A fascinating feature of EPO is that, although glycine and proline residues are 
known to be strong breakers of α- helix and β-sheet structures, they are randomly 
distributed through most of the molecule.  These residues are not found in regions 4-27 
and 130-150.  Therefore, there is a high degree of α- helix structures in these regions 
(Por-Hsiung, et al, 1985).  The α- helix content was revealed by the near and far- UV 
CD spectra to be around 50%.  The near and far- UV CD spectra are used to uncover the 
secondary structure of a molecule (Por-Hsiung, et al, 1985).  Another study of the α- 
helix and β-sheet structures using a computer program based on method used by Chou 
and Fasman (Por-Hsiung L et al, 1985), α- helix content is about 36% whereas β-sheet 
content is about 28%.  A different analysis by the method used by Garnier et al (Garnier 
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et al, 1978), predicts that the α- helix content is to be 42% together with β-sheet content 
of about 21% (Figure 2.2).  
 
 
 
Figure 2.2: Protein structural unit of a single polypeptide chain of amino acids. 
The purple cylinders represent alpha helixes and the yellow arrows represent beta 
sheets. Adapted from http://www.sciencephoto.com/media/7778/enlarge 
 
 
                The glycoprotein is highly glycosylated (S.B Krantz, 1991).  It has three N-
glycosylation sites at Asn24, Asn38 and Asn83 and one O-linked glycosylation site at 
Ser126 attached to the polypeptide backbone (Figure 2.3) (J.W. Fisher, 2003, Venke, el 
at, 2001).  The polypeptide chain synthesis of a glycoprotein is genetically regulated, 
whereas, the oligosaccharide chains are processed and attached by a series of enzyme 
reactions.  Therefore, glycoproteins appear as a mixture of glycoforms, which have 
shown to be cell, species, polypeptide and site specific (Parekh, et al, 1987, Parekh, et al 
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1989, Rudd, et al, 1997, Zerfaoui, et al, 1996).  Consequently, each glycoprotein has a 
reproducible and characteristic glycosylation pattern (Kanazawa, et al, 1999, Storring, 
et al, 1998).  It was estimated by Wide and Bengtsson that the serum EPO contains 20-
30 different forms found in the blood of anaemic patients (Lasne, 2006).   
 
 
Figure 2.3: The primary structure of erythropoietin presenting the outline of 165 
amino acids. There are two disulfide bonds joining the molecule together between 
cysteines 29 and 33, cysteines 6 and 161. Three N-lined sugars are existing at 
asparagines 24, 38,and 83 and one O-linked sugars is existing at serine 126. 
Adapted from http://www.sciencephoto.com/media/7778/enlarge 
 
                The carbohydrate content contributes to approximately 40% of the total 
molecular mass of the molecule (Choi, et al, 1996, Venke, et at, 2001).  Glycosylation is 
most important for the in vivo and in vitro biologic activity of the hormone.  These 
oligosaccharide units of the glycoproteins provide a range of functions, including 
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folding of generating polypeptide chains.  This process takes place in the endoplasmic 
reticulum (Venke, et at, 2001).  The endoplasmic reticulum protects the protein moieties 
from modulation of the biologic activities as well as from the action of proteases (Imai 
N et al, 1990, Rademacher, et al, 1988).  Modifications or elimination of the glycan 
chains lead to alterations in its activities (Choi, et al, 1996, Venke, et at, 2001).  
Moreover, the macromolecule has a biologic marker that prevents the hormone from 
depuration in the liver before it reaches its physiologic target known as sialic acids.  
These residues are located in strategic positions of the polysaccharide chain (Choi D et 
al, 1996).  Studies showed that the number of sialic acid residues and the N-linked 
oligosccharides branching pattern modify the pharmacodynamics, biologic activity and 
catabolism speed of the EPO molecule (Fukuda, et al, 1989, Higuchi, et al, 1992, Imai 
N et al, 1990).  Human EPO encloses two disulfide bonds, one formed between Cys7 
and Cys161, the other between Cys29 and Cys33, noting that the second disulfide bond 
is sandwiched between two proximate glycosylated sites, Asn24 and Asn38 (Por-
Hsiung L et al, 1985).  After entering the blood stream, EPO has estimated half-life of 6 
to 8 hours (Adamson, 1996).  The production of an in vivo active hEPO needs the 
biosynthetic machinery of higher cells.  For that reason at present, all EPO that is on 
hand in the market is produced in mammalian cell culture (F.K. Lin et al, 1985, K. 
Jacobs et al, 1985). 
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2.3.1.2 Recombinant EPO (Exogenous)  
 
              There are a number of pharmaceuticals of recombinant EPO (rEPO) that are 
available in the market for clinical use.  They are classified, according to the 
manufacturing methods, into epoetin alpha, epoetin beta, Novel Erythropoiesis 
Stimulating Protein (NESP or darbepoetin alpha), Continuous Erythropoietin Receptor 
Activator (CERA), and others (Venke, el at, 2001, Estela, et al, 2009).  The peptide 
sequence of the rEPOs is homogenous to the natural or endogenous form, however they 
differ in their carbohydrate site (Choi, et al, 1996).  This observation in the composition 
and disposition of the polysaccharide structure is due to the different sources of 
synthesis, as well as manufacturing sites from different parts of the world (River, et al, 
2003).     
 
                Epoetin alpha and beta are produced by Hamster cell lines, such as the 
Chinese hamster ovary (CHO) and baby hamster kidney (BHK).  Those two organs are 
the common hosts for the recombinant human glycoprotein production intended for 
therapeutic use.   The glycosylation pattern of the proteins produced by these cells is 
qualitatively similar to those in human cells; however, some carbohydrate motifs are 
explicit for human tissues and are not synthesized by these cells.  The reason for that is 
that they are deficient in the appropriate sugar-transferring enzymes, including sialyl-α 
2-6 transferase, bisecting N-acetyl glucosamine transferase, and α 1-3/4 fucosyl 
transferase (Venke, et al, 2001).  In human serum, the lack of tetra-acidic 
oligosaccharide structures is the most important difference between circulating hEPO 
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and rEPO as revealed by charge analysis (Venke, et al, 2001).  The charge analysis 
shows that rEPO has a reasonably high content of tetra-sialylated oligosaccharide 
structures compared to circulating hEPO.  Epoetin alpha contains 19% of tetra-
sialylated oligosaccharide while in epotin beta the tetra-acidic glycans dominate the 
structure and has been estimated to be 46%.  The half life of glycoproteins increases by 
the terminal sialic acids content.  This is fundamental with respect to in vivo bioactivity 
of hEPO (Ashwell et al, 1974, Ashwell, et al, 1982, Fukuda, et al, 1989, Goldwassaer  
et al, 1974, Lowy PH et al, 1960).    
 
2.4 Techniques to Detect Recombinant Erythropoietin 
 
                The importance and challenge of detecting EPO misuse in sports has 
prompted the request to develop several strategies for EPO detection (Jordi, et al, 2007).   
One of these strategies, developed by Parisotto et al, so-called indirect method that 
monitors the physiological and biochemical effects of EPO administration.   This 
method measures blood parameters such as haematocrit, haemoglobin, and reticulocytes 
in the whole blood that has been extracted from athletes.  This approach depends on 
using more than one parameter that would increase the test specificity and decrease the 
possibility of false positive (Jordi, et al, 2007).   As a substitution, the structural 
differences between endogenous human EPO and recombinant EPO, which lies in the 
glycosylation pattern of the protein, can be used for a more definitive direct method 
(Jordi, et al, 2007).  The heterogeneity can then be demonstrated in the form of multiple 
glycoforms that differ in the charge, weight and sugar composition. 
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2.4.1 Isoelectric Focusing 
 
                Isoelectric focusing (IEF) is the official method approved by the IOC and the 
WADA for rEPO detection in urine EPO test (Estela, et al, 2009). Currently, IEF is the 
only detection method that is capable of differentiation between endogenous and 
recombinant forms of EPO at low concentration levels found in biological fluids.  The 
concentration of hEPO found in urine and/or plasma is estimated to be ≤ 200 ng/L 
(Estela, et al, 2009). 
 
                In the year 2000, Lasne and de Ceaurriz reported the first data on the method 
that was able to detect and differentiate between endogenous and recombinant EPO in 
urine. Briefly, the method consists of 4 major steps, 1- urine concentration, 2- 
Isoelectric Focusing (IEF) separation, 3- double blotting and 4- chemiluminescence 
detection (Jordi, et al, 2007).  In the first step, an aliquot of 20 ml urine is concentrated 
by ultra-filtration to a volume of approximately 20 µl via a 30-kDa molecular mass cut-
off.  Then the amount collected is applied onto an IEF gel with a pH gradient from 2-6.  
Following that the separation of different isoforms is initiated by the applied electrical 
field.  The separation goes on the basis of their respective isoelectric points (Ip).  Once 
the separation is accomplished, the gel is subjected to a double-blotting process where 
all proteins are transferred from the gel to a polyvinyldifluride (PVDF) membrane.  
Mouse anti-EPO monoclonal antibodies are used to identify EPO, next the antibodies 
are detached and transferred to a second PVDF membrane.  Finally, the antibodies are 
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identified by anti-mouse biotinylated antibody (Jordi, et al, 2007).  To complete the 
steps, a streptavidin peroxidase complex is added to the gel in the presence of luminol 
and hydrogen peroxidase to generate chemiluminescence (Figure 2.4).  
 
 
 
Figure 2.4: Simple diagram summaries the 1st blotting, 2nd blotting and the 
chemiluminescene step that visualizes the IEF bands. Adapted from (Joaquim M. 
2011) 
  
 
The end result of this method is a representation of a set of bands that shows groups of 
EPO isoforms as shown in (Figure 2.5). 
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Figure 2.5: Isoelectric focusing images obtained for the analysis of recombinant 
EPO. Adapted from WADA technical document – TD2009EPO   
                On behalf WADA, Peltre and Thomman reviewed thoroughly the newly 
developed method and validated it despite its complexity and cost.  Also Peltre and 
Thomman suggested some improvements in some of the steps, fields of future 
development and research (Jordi, et al, 2007).   
 
                During the Sydney Olympic Games in the year 2000 the IEF method for EPO 
was used in connection with the indirect blood method, though no sample was found to 
contain rEPO during that event.  The weakness of this method is that the detection of 
rEPO bands do not have a unique pattern, nevertheless they extend through the 
endogenously EPO pI values.  Accordingly, there was a need to establish a certain 
objective criteria for the presence and identification of rEPO.   This is a qualitative 
method in which the detection criterion proposed were established by observing the 
variation or ratio concerning the intensity of the most plentiful bands in the exogenous 
